| abstract |
The present invention provides combinations of decitabine derivatives and other active agents including T cell activators, cancer vaccines and adjuvants. Some derivatives of decitabine show excellent chemical stability and shelf life, and have similar physiological activities. Methods of using the combinations to treat one or more of myelodysplastic syndromes, cancer, hematological disorders, or diseases associated with abnormal hemoglobin synthesis are described. |